BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20208319)

  • 1. Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Bussom S; Saif MW
    JOP; 2010 Mar; 11(2):128-30. PubMed ID: 20208319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Bussom S; Saif MW
    JOP; 2010 Mar; 11(2):131-4. PubMed ID: 20208320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative care from the beginning of treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Lazenby JM; Saif MW
    JOP; 2010 Mar; 11(2):154-7. PubMed ID: 20208326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2010 Mar; 11(2):124-7. PubMed ID: 20208318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Merl MY; Li J; Saif MW
    JOP; 2010 Mar; 11(2):148-50. PubMed ID: 20208324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Richter J; Saif MW
    JOP; 2010 Mar; 11(2):139-43. PubMed ID: 20208322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection and screening of pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Gonda TA; Saif MW
    JOP; 2011 Mar; 12(2):83-5. PubMed ID: 21386626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Li J; Merl MY; Saif MW
    JOP; 2010 Mar; 11(2):151-3. PubMed ID: 20208325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pancreatic carcinoma: diagnosis].
    Scheurer U
    Ther Umsch; 1996 May; 53(5):377-86. PubMed ID: 8685856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
    Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of early-stage pancreatic cancer biomarkers.
    Expert Rev Mol Diagn; 2008 Nov; 8(6):675. PubMed ID: 18999919
    [No Abstract]   [Full Text] [Related]  

  • 16. Early detection of pancreatic cancer.
    Eguia V; Gonda TA; Saif MW
    JOP; 2012 Mar; 13(2):131-4. PubMed ID: 22406583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Kang SP; Saif MW
    JOP; 2010 Jul; 11(4):334-5. PubMed ID: 20601806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of pancreatic cancer.
    Furukawa H; Okada S; Kakizoe T
    Hepatogastroenterology; 1999; 46(25):4-7. PubMed ID: 10228757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.